ArticleBritish journal of pharmacology2003
Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).
Article in British journal of pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 72 citations in OpenAlex.
- Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin.American journal of respiratory cell and molecular biology · 2015Trial
- Review
- Subaqueous acoustic pressure system based one day heterotypic pseudo-islet spheroid formation with adipose derived stem cells for graft survival-related function enhancement.Bioactive materials · 2025Article
- Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies.Biomarker research · 2025Review
- Crocin Combined with Cisplatin Regulates Proliferation, Apoptosis, and EMT of Gastric Cancer Cells via the FGFR3/MAPK/ERK PathwayCurrent cancer drug targets · 2024Article
- Angiogenic signaling pathways and anti-angiogenic therapy for cancer.Signal transduction and targeted therapy · 2023Review
- Enhancement of Wound Healing Efficacy by Increasing the Stability and Skin-Penetrating Property of bFGF Using 30Kc19α-Based Fusion Protein.Advanced biology · 2021Article
- MicroRNA-210 improves perfusion recovery following hindlimb ischemia via suppressing reactive oxygen species.Experimental and therapeutic medicine · 2020Article
- Sustained Release of Basic Fibroblast Growth Factor (bFGF) Encapsulated Polycaprolactone (PCL) Microspheres Promote Angiogenesis In Vivo.Nanomaterials (Basel, Switzerland) · 2019Article
- Curcumin improves perfusion recovery in experimental peripheral arterial disease by upregulating microRNA-93 expression.Experimental and therapeutic medicine · 2019Article
- SNRK (Sucrose Nonfermenting 1-Related Kinase) Promotes Angiogenesis In Vivo.Arteriosclerosis, thrombosis, and vascular biology · 2018Article
- Comparative Evaluation for Potential Differentiation of Endothelial Progenitor Cells and Mesenchymal Stem Cells into Endothelial-Like Cells.International journal of stem cells · 2016Article
- Fibroblast growth factor 2 dimer with superagonist in vitro activity improves granulation tissue formation during wound healing.Biomaterials · 2016Article
- The role of FGF2 in migration and tubulogenesis of endothelial progenitor cells in relation to pro-angiogenic growth factor production.Molecular and cellular biochemistry · 2015Article
- Fibroblast growth factor-2 regulates human cardiac myofibroblast-mediated extracellular matrix remodeling.Journal of translational medicine · 2015Article
- Cellular and pharmacological targets to induce coronary arteriogenesis.Current cardiology reviews · 2014Review
- Transforming growth factor-β-induced differentiation of airway smooth muscle cells is inhibited by fibroblast growth factor-2.American journal of respiratory cell and molecular biology · 2013Article
- Therapeutic angiogenesis: controlled delivery of angiogenic factors.Therapeutic delivery · 2012Review
- Challenging the surgical rodent hindlimb ischemia model with the miniinterventional technique.Journal of vascular and interventional radiology : JVIR · 2011Article
- DNA electrotransfer to the skin: a highly translatable approach to treat peripheral artery disease.Gene therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Therapeutic angiogenesis represents an attempt to relieve inadequate blood flow by the directed growth and proliferation of blood vessels. Neovascularization is a complex process involving multiple growth factors, receptors, extracellular matrix glycoproteins, intracellular and extracellular signaling pathways, and local and bone-marrow-derived constituent cells, all responding to a symphonic arrangement of temporal and spatial cues. In cardiovascular disease, patients with refractory angina and lower extremity intermittent claudication seem most amenable to early tests of therapeutic angiogenesis. Monotherapy with the recombinant protein basic fibroblast growth factor (FGF-2) has been tested in six human trials. These have shown provisional safety, and two have provided 'proof of concept' for the strategy of therapeutic angiogenesis. One large randomized phase II trial failed to show significant efficacy in coronary artery disease. Another showed significant efficacy in peripheral artery disease, although the magnitude of benefit was disappointing at the dose tested. This overview details the suitable clinical trial design and further steps toward the clinical development of FGF-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.